摘要
目的了解郑州地区新型冠状病毒疫苗接种情况及接种后体内产生抗体情况,为新冠病毒的防控提供依据。方法收集1437例病例的血清和个案资料信息,采用磁微粒化学发光法检测病例血清的新冠病毒IgG抗体水平,对病例的血清检测结果和个案资料信息进行统计分析。结果0~3岁年龄组的307例全部未接种疫苗,4~6岁的学龄前儿童接种率为63.95%,7~59岁的接种率89.53%,60岁及以上老年人的接种率为70.00%。接种3剂次新冠病毒疫苗病例的IgG阳性率最高,为90.00%,60岁及以上的IgG阳性率明显低于18~59岁。男/女性别间接种新冠疫苗后产生IgG的总体阳性率无明显差别。4~17岁未成年组最后一针接种剂次有20.93%是在2022年内接种的,18岁及以上的成年组有58.70%为2022年内接种的。结论郑州市4~6岁学龄前儿童和60岁以上老人的新冠疫苗接种率较低,多数4~17岁未成年人新冠疫苗最后剂次的接种时间为2022年以前,新冠抗体IgG阳性率较低。
Objective To understand the vaccination pattern of COVID-19 vaccine in Zhengzhou and the antibody status in the body after vaccination,so as to provide a reference basis for prevention and control of SARS-CoV-2.Methods Serum and clinical information of 1437 cases were collected,and the novel coronavirus IgG antibody level in the serum of the cases was detected by magnetic particle chemiluminescence method.The results of serum detection and case information were statistically analyzed.Results All 307 cases in the age group of 0 to 3 years were not vaccinated.The vaccination rate of preschool children aged 4 to 6 years old was 63.95%,the vaccination rate of 7 to 59 years old was 89.53%,and the vaccination rate of the elderly aged 60 and above was 70.00%.The highest positive rate of IgG was 90.00 percent in cases of three doses of the new coronavirus vaccine.The positive rate of IgG in 60 years old and over was significantly lower than that in 18-59 years old.There was no significant difference in the overall positive rate of IgG produced by COVID-19 vaccine between male and female groups.20.93%of the final doses in the underage group aged 4-17 were administered in 2022,while 58.70%of the adult group aged 18 and above were administered within 2022.Conclusion COVID-19 vaccine vaccination rate of preschool children aged 4-6 and elderly people over 60 years old in Zhengzhou is low.The last dose of COVID-19 vaccine for most minors aged 4-17 is before 2022,and the positive rate of COVID-19 antibody IgG is low.
作者
董柯
王琳
邵束钰
程春荣
杜浩峰
DONG Ke;WANG Lin;SHAO Shuyu;CHENG Chunrong;DU Haofeng(Zhengzhou Center for Disease Control and Prevention,Zhengzhou 450007,China;Tuberculosis Prevention and ControlDepartment of Xuchang Jian’an District Center for Disease Control and Prevention,Xuchang 461100,China)
出处
《标记免疫分析与临床》
CAS
2023年第12期2082-2085,2141,共5页
Labeled Immunoassays and Clinical Medicine